Evidence map›Paper›PMID 35872304›Full record

ArticleTransplantation and cellular therapy2022

Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation.

Seth J Rotz, Jean C Yi, Betty K Hamilton, Wei Wei, Jaime M Preussler, Jan Cerny, Abhinav Deol, Heather Jim, Nandita Khera, Theresa Hahn and 15 more

Open access · greenAbstract read
In one paragraph

Article in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 2 countries.

Seth J RotzDepartment of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: rotzs@ccf.org.
Jean C YiFred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington.
Betty K HamiltonDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
Wei WeiDepartment of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio.
Jaime M PreusslerNational Marrow Donor Program/Be The Match; Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
Jan CernyUniversity of Massachusetts, Chan Medical School, Department of Medicine, Div. of Hematology/Oncology, Worcester, Massachusetts.
Abhinav DeolWayne State University, Karmanos Cancer Institute, Detroit, Michigan.
Heather JimDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
Nandita KheraMayo Clinic Arizona, Phoenix, Arizona.
Theresa HahnDepartment of Cancer Prevention & Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Shahrukh K HashmiDepartment of Medicine, SSMC, Abu Dhabi, UAE, Division of Hematology, Department of Medicine, Mayo Clinic, Minnesota.
Shernan HoltanDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Samantha M JaglowskiThe Ohio State University, Columbus, Ohio.
Alison W LorenPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Joseph McGuirkDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas.
Jana ReynoldsBlood & Marrow Transplant, Baylor University Medical Center, Dallas, Texas.
Wael SaberDepartment of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Bipin N SavaniDivision of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Patrick StiffLoyola University Stritch School of Medicine, Maywood, Illinois.
Joseph UbertiWayne State University, Karmanos Cancer Institute, Detroit, Michigan.
John R WingardUniversity of Florida, Gainesville, Florida.
William A WoodDivision of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
K Scott BakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Navneet S MajhailSarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee.
Karen L SyrjalaFred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington.
Cleveland Clinic · USFred Hutch Cancer Center · USWayne State University · USBaylor University Medical Center · USLoyola University Chicago · USMayo Clinic Hospital · USMedical College of Wisconsin · USMoffitt Cancer Center · USNational Marrow Donor Program · USRoswell Park Comprehensive Cancer Center · USSarah Cannon · USSheikh Shakhbout Medical City · AEThe Ohio State University · USThe University of Kansas Cancer Center · USUniversity of Florida · USUniversity of Massachusetts Chan Medical School · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · USVanderbilt University Medical Center · US

Funding

Institutional Career Development CoreKL2TR002547 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI DWEIK, RAED A. · 2018 to 2022
$7.7M
Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6M
Improving Survivorship Care for Adolescents and Young Adults: a Mixed Methods Study of Alignment with the National Standards for Survivorship CareU01CA246659 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S · 2020 to 2025
$3.6M
Internet Studies to Enhance Long Term Survivorship after Hematologic MalignancyR01CA160684 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SYRJALA, KAREN LESLIE · 2011 to 2015
$3.4M
NCATS NIH HHS KL2 TR002547NCI NIH HHS R01 CA160684NCI NIH HHS R01 CA215134NCI NIH HHS U01 CA246659Patient-Centered Outcomes Research Institute CD-12-11-4062
6 · The paper itself

Abstract

Young adults (YA), age 18 to 39 years, are at a stage of life that may make them more vulnerable than older adults to impairments in health-related quality of life (HRQOL) during and after hematopoietic cell transplantation (HCT). Health self-efficacy (HSE), the belief that one can implement strategies to produce a desired health outcome, has been associated with health outcomes in oncology research. Little is known about HRQOL or HSE in YA HCT survivors compared with older HCT survivors. Given the age-specific psychosocial challenges facing YA HCT recipients and research on non-transplant YA cancer survivors, we hypothesized that YA survivors would have worse post-HCT HRQOL compared with older adults, and that among YA HCT survivors, higher levels of HSE would be associated with higher levels of HRQOL and lower levels of cancer-related distress. This was a cross-sectional secondary analysis of 2 combined baseline datasets from multicenter studies of HCT survivors approached for participation in clinical trials of survivorship interventions. Participants from 20 transplantation centers in the United States were at 1 to 10 years post-HCT and age ≥18 years at the time of study enrollment, had no evidence of disease relapse/progression or subsequent malignancies, and could read English adequately to consent for and complete assessments. Medical record and patient-reported data were obtained for demographics and HCT-related clinical factors and complications (eg, total body irradiation, chronic graft-versus-host disease [cGVHD]). Participants completed surveys on HRQOL, including the Short-Form [SF]-12, HSE, and Cancer and Treatment Distress (CTXD), which includes 6 subscales and reports an overall mean score. On the SF-12, both the Mental Component Score (MCS) and Physical Component Score (PCS) were calculated. Two cohorts were compared: YAs (age 18 to 39 years at transplantation) and older adults (age ≥40 years at transplantation). Multiple linear regression analyses identified factors associated with HSE, PCS, MCS, and CTXD in YAs. In this analysis of 979 survivors, compared with the older adults, the YA participants had lower median mental health scores (SF-12 MCS: 48.40 versus 50.23; P = .04) and higher cancer-related distress (CTXD: .96 versus .85; P = .04), but better physical health (SF-12 PCS: 48.99 versus 47.18; P = .049). Greater overall cancer-related distress was driven by higher levels of uncertainty, financial concern, and medical demand subscales for YAs compared with older adults. Young adults also had lower HSE (2.93 versus 3.08; P = .0004). In a multivariate model, HSE was strongly associated with age group (P = .0005) after adjusting for multiple other transplantation-related factors. Among YAs, HSE was associated with the SF-12 MCS and PCS and the CTXD, and HSE remained significant after adjusting for other transplantation-related factors. Overall, the YA HCT survivors had lower mental health, increased cancer-related distress, and lower levels of HSE compared with the older adults. Although the direction of these effects cannot be determined with these data, the strong association between HSE and HRQOL among YAs suggests that targeting interventions to improve HSE may have broad impact on health outcomes.

Indexed as

Cancer SurvivorsHematopoietic Stem Cell TransplantationQuality of LifeAdolescentAdultCross-Sectional StudiesHumansNeoplasmsUnited StatesYoung AdultHCTHRQOLHSESelf-efficacySurvivorshipYoung adult

Identifiers

PMID35872304
PMCPMC9547939
OpenAlexW4286449531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.